Hemogenyx Pharmaceuticals (LON:HEMO) Stock Price Down 0.9% – Here’s Why

Hemogenyx Pharmaceuticals Plc (LON:HEMO – Get Free Report) dropped 0.9% during trading on Monday. The company traded as low as GBX 540 and last traded at GBX 565. 1,286 shares were traded during mid-day trading, a decline of 94% from the average daily volume of 23,341 shares. The stock had previously closed at GBX 570.

Hemogenyx Pharmaceuticals Stock Down 0.9%

The company’s 50 day moving average price is GBX 581.62 and its two-hundred day moving average price is GBX 753.42. The company has a quick ratio of 6.72, a current ratio of 4.04 and a debt-to-equity ratio of 42.86. The stock has a market cap of £38.97 million, a P/E ratio of -4.32 and a beta of 1.49.

Hemogenyx Pharmaceuticals (LON:HEMO – Get Free Report) last released its quarterly earnings data on Monday, September 28th. The company reported GBX (101.70) earnings per share for the quarter.

About Hemogenyx Pharmaceuticals

(Get Free Report)

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.

Recommended Stories

Receive News & Ratings for Hemogenyx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemogenyx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.